← boardnext 2026-11
IMUX
Immunic AGdistress 2/10 · well-funded / low risk$14.82-2%today-4% from 52w high
Neurology 1
Lead: progressive multiple sclerosis · target DHODH · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$187M
Runway
2.3 yrs
Shares 1y
-86%
Price & events
+115.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-1.4%
1W
-1.7%
1M
+61.4%
3M
+115.7%
6M
+48.6%
1Y
+1.5%
2Y
-83.8%
5Y
-90.8%
All
Overview
- Market Cap
- $201.87M
- Volume
- 6.46K
- 52 Week Range
- $5.10 – $15.41
- Total Shares
- 13.62M
- Float Shares
- 11.84M
- Short %
- 12.33%
- % Held by Insiders
- 0.97%
- % Held by Institutions
- 46.90%
- RVOL
- 0.04x
- Beta
- 1.38
Pipeline stages · 1 programs
IMU-838 tablets
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2027-01-15 | Phase 3 | IMU-838 tablets | Multiple Sclerosis, Relapsing-Remitting | — | active not recruiting |
| 2026-11 Estimated 50% readout ~2027-01-15 | Phase 3 | IMU-838 tablets | Multiple Sclerosis | — | active not recruiting |
| 2025-01-07 | Phase 2 | IMU-838, Placebo matching IMU-838 | Multiple Sclerosis | 450 | unknown |
Catalyst news & presentations · 7
- by the end of 2026Guided 70%readoutPhase 3vidofludimus calcium · Top-line data from phase 3 ENSURE trialsSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- May 27-29, 2026; presented on May 28conferencedata presentationsecondaryPhase 2vidofludimus calcium (IMU-838) · Presented additional data from phase 2 CALLIPER trial at CMSC 2026SEC 8-K
- September 24-26, 2025conferencedata presentationsecondaryPhase 2vidofludimus calcium · Oral and poster presentations at ECTRIMS including Phase 2 CALLIPER trial results.SEC 8-K
- April 30, 2025readoutPhase 2vidofludimus calcium · Phase 2 CALLIPER trial topline data announcedSEC 8-K
- February 20, 2025conferencedata presentationsecondaryIMU-856 · Digital oral presentation at ECCO 2025 on biomarker findings from phase 1b studySEC 8-K
- September 2024conferencedata presentationsecondaryvidofludimus calcium · MS R&D Day to provide detail on vidofludimus calcium development programSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-22B. Riley SecuritiesBuy
- 2026-04-30HC Wainwright & Co.Buy
- 2026-04-17StifelBuy
- 2026-04-15D. Boral CapitalBuy → Hold
- 2026-03-24GuggenheimBuy
- 2026-03-02HC Wainwright & Co.Buy
Competitors — DHODH
- none identified
Recent news
- 2026-07-16abrdn discloses 6.05% Immunic (IMUX) stake held for clients - Stock Titan
- 2026-07-14Immunic posts updated corporate presentation under Regulation FD - TradingView
- 2026-07-14Immunic (NASDAQ: IMUX) releases new presentation on pipeline and plans - Stock Titan
- 2026-07-09Immunic to Participate in Investor Conferences in July - PR Newswire
- 2026-07-07Immunic director granted options for 25,370 shares | IMUX Insider Trading - Stock Titan
- 2026-07-07Immunic Names CEO Erik Lundgren to Board - The Globe and Mail
- 2026-07-07Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80 - Stock Titan
- 2026-07-07IMMUNIC (IMUX) director Barclay Phillips awarded 25,370 stock options as equity pay - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.